Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany

References

• Swerdlow SC, Harris NL, Jaffe ES, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer publications, World Health Organization Press. Revised 4th ed.; Vol. 2. 2008.
   Google Scholar
• (IHME) Institute for Health Metrics and Evaluation. GBD Compare. Seattle (WA): IHME, University of Washington 2015 [accessed February 2019]. Available from: http://vizhub.healthdata.org/gbd-compare
   Google Scholar
• Krebs in Deutschland für 2013/2014. 11. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin; 2017.
   Google Scholar
• Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252–264.
   PubMed Web of Science ®Google Scholar
• Pulte D, Jansen L, Castro FA, et al. GEKID Cancer Survival Working Group. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol. 2015;171:189–196.
   PubMed Web of Science ®Google Scholar
• Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35.
   PubMedGoogle Scholar
• Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017;281:365–382.
   PubMed Web of Science ®Google Scholar
• Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int. 2016;113:470–476.
   PubMed Web of Science ®Google Scholar
• Fragoulakis V, Kastritis E, Psaltopoulou T, et al. Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Manag Res. 2013;5:37–48.
   PubMedGoogle Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143:537–540.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–1634.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327–1337.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–3901.
   PubMed Web of Science ®Google Scholar
• Cook G, Zweegman S, Mateos MV, et al. A question of class: treatment options for patients with relapsed and/or refractory multiple myeloma. Crit Rev Oncol Hematol. 2018;121:74–89.
   PubMed Web of Science ®Google Scholar
• Durer C, Durer S, Lee S, et al. Treatment of relapsed multiple myeloma: evidence-based recommendations. Blood Rev. 2020; 39:100616.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766.
   PubMed Web of Science ®Google Scholar
• Steinmetz HT, Singh M, Lebioda A, et al. Management of patients with relapsed/refractory multiple myeloma (RRMM) treated with proteasome inhibitor based therapy at first relapse in routine clinical practice in Germany. Blood. 2018;132:1953.
   Google Scholar
• Steinmetz HT, Singh M, Lebioda A, et al. Patient characteristics and outcomes of relapsed/refractory multiple myeloma in patients treated with proteasome inhibitors in Germany. Oncol Res Treat. 2020;43:449–459.
   PubMed Web of Science ®Google Scholar
• LAUER-FISCHER GmbH. Pharmaceutical information for all drugs and contracts registered in Germany. [accessed February 2018]. Available from: https://www.cgm.com/lauer-fischer/loesungen_lf/lauer_taxe_lf/lauertaxe_online_4_0/online_en.de.jsp
   Google Scholar
• InEK GmbH. Institute for the remuneration system in the hospital, 2007–2019. Germany. [accessed February 2018]. Available from: https://www.g-drg.de/G-DRG-System_2018/Grouper_Zertifizierung/Grouper_Zertifizierung_2018
   Google Scholar
• StataCorp. 2017. Stata statistical software: release 15. College Station TSL.
   Google Scholar
• Merz M, Kellermann L, Poenisch W, et al. Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. Ann Hematol. 2017;96:987–993.
   PubMed Web of Science ®Google Scholar
• Gengenbach L, Reinhardt H, Ihorst G, et al. Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. Leuk Lymphoma. 2018;59:2692–2699.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Multiple myeloma. Version 4. 2020 [accessed 2020 May 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
   Google Scholar
• Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101–119.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101:396–406.
   PubMed Web of Science ®Google Scholar
• Woermann B, Driessen C, Einsele H, et al. Mutiple myeloma. 2018 [accessed 2020 Jun 2]. Available from: https://www.onkopedia.com/de/onkopedia/guidelines/multiples-myelom/@@guideline/html/index.html
   Google Scholar
• Raab MS, Fink L, Schoen P, et al. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. Br J Haematol. 2019;185:981–984.
   PubMed Web of Science ®Google Scholar
• Gonzalez-McQuire S, Yong K, Leleu H, et al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J Med Econ. 2018;21:450–467.
   PubMed Web of Science ®Google Scholar
• Blommestein HM, Verelst SG, de Groot S, et al. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. Eur J Haematol. 2016;96:198–208.
   PubMed Web of Science ®Google Scholar
• Gaultney JG, Franken MG, Tan SS, et al. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther. 2013;38:41–47.
   PubMed Web of Science ®Google Scholar
• Petrucci MT, Calabrese E, Levi A, et al. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. Tumori. 2013;99:e193–e202.
   PubMedGoogle Scholar
• Engelhardt M, Ihorst G, Singh M, et al. Real-world evaluation of health-related quality of life in patients with multiple myeloma in Germany. Clin Lymphoma Myeloma Leuk. 2020. DOI:https://doi.org/10.1016/j.clml.2020.10.002
   Google Scholar
• Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27:1959–1969.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Delforge M, Facon T, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32:1542–1560.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Moreau P, Dimopoulos MA, et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019;9:23.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Delea T, Panjabi S, et al. Burden of disease progression in patients with multiple myeloma who have received at least one line of therapy in the US. Blood. 2018;132:4754.
   Web of Science ®Google Scholar
• Despiegel N, Touboul C, Flinois A, et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk. 2019;19:e13–e28.
   PubMed Web of Science ®Google Scholar
• Sekine L, Ziegelmann PK, Manica D, et al. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: a systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials. Crit Rev Oncol Hematol. 2019;143:102–116.
   PubMed Web of Science ®Google Scholar
• Zweegman S, Engelhardt M, Larocca A, EHA SWG on ‘Aging and Hematology’. Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol. 2017;29:315–321.
   PubMed Web of Science ®Google Scholar
• Arikian SR, Milentijevic D, Binder G, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015;31:1105–1115.
   PubMed Web of Science ®Google Scholar
• Zhou X, Xia J, Mao J, et al. Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: a retrospective analysis from the Chinese experience. Hematology. 2016;21:280–286.
   PubMed Web of Science ®Google Scholar
• Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8:204–215.
   PubMed Web of Science ®Google Scholar
• Armoiry X, Fagnani F, Benboubker L, et al. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. J Clin Pharm Ther. 2011;36:19–26.
   PubMed Web of Science ®Google Scholar
• Chen CC, Parikh K, Abouzaid S, et al. Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib. J Manag Care Spec Pharm. 2017;23:236–246.
   PubMed Web of Science ®Google Scholar
• Gooding S, Lau IJ, Sheikh M, et al. Double relapsed and/or refractory multiple myeloma: clinical outcomes and real world healthcare costs. PLoS One. 2015;10:e0136207.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Panjabi S, Sharma A, et al. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone. J Med Econ. 2019;22:818–829.
   PubMed Web of Science ®Google Scholar
• Lin HM, Davis KL, Kaye JA, et al. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019;2019:4625787.
   PubMedGoogle Scholar